When the US Food and Drug Administration (FDA) rejected Lykos Therapeutics’ new drug application for…
Category:
Investing
-
-
-
Investing
Group Eleven Intersects 12.0m of 2.30% Cu and 560 g/t Ag, Including 6.4m of 3.72% Cu and 838 g/t Ag, Demonstrating High-Grade Copper and Silver Potential at Ballywire
by adminGroup Eleven Resources Corp. (TSXV: ZNG) (OTC Pink: GRLVF) (FSE: 3GE) (‘Group Eleven’ or the…